Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
8 Results for "
IFN synthesis
" in MedChemExpress (MCE) Product Catalog:
Products (8)
8 Results for "IFN synthesis" in MCE Product Catalog:
Cat. No.: HY-P5581
CAS No.: 347884-61-1
Target:
Research Areas:
Synonyms: Daxalipram
Research Areas:
Mesopram (Daxalipram) is an orally active phosphodiesterase (PDE) 4 inhibitor. Mesopram inhibits the synthesis of proinflammatory cytokines TNF-α and IFN-γ. Mesopram demonstrates efficacy in ameliorating Dextran sulfate sodium (DSS) (HY-116282C)-induced murine colitis. Mesopram can be used for the study of chronic inflammatory diseases .
Cat. No.: HY-173070
CAS No.: 2275612-76-3
Research Areas:
TLR7 agonist 29 (Compound 1) is the agonist for TLR7 with an EC50 of 5.2 nM for human TLR7 (EC50 for mouse TLR7 is 48.2 nM). TLR7 agonist 29 activates bone marrow-derived macrophages (BMDMs), stimulates myeloid cells in the tumor microenvironment, promotes the expression of PD-L1, CD86 and IFN-α. TLR7 agonist 29 can be used as payload for synthesis of ADC .
Cat. No.: HY-182503
CAS No.: 144928-48-3
Target:
Research Areas:
GP515 is a potent and selective adenosine kinase inhibitor with a human IC50 of 4 nM. GP515 exerts tissue protective effects, produces long-lasting hepatic microcirculation effects after hemorrhagic shock, and induces dose- and time-related VEGF mRNA and protein expression in normoxic rat myocardial myoblasts, with additive VEGF increases during mild hypoxia and no effect during severe hypoxia. GP515 suppresses IFNγ synthesis and CD69 expression in DSS-induced colitis. GP515 also shows a dose-dependent suppression of TNF-α production with an IC50 of 80 μM and can be reversed in the presence of the cAMP antagonist (Rp)-cAMPS. Combinations of GP515 with either adenosine or rolipram led to an additive inhibition of TNF-α synthesis. GP515 can be used for the research of hemorrhagic shock .
Cat. No.: HY-184969
Research Areas:
NUCC-0227579 is a VHL-recruiting PROTAC degrader targeting CD73, with a DC50 of 0.32 μM. NUCC-0227579 synergistically mediates CD73 degradation through the ubiquitin-proteasome pathway and the lysosomal pathway. NUCC-0227579 inhibits the conversion of AMP to adenosine, abrogates adenosine-mediated immunosuppression, upregulates the activities of the NF-κB and NFAT pathways, and enhances the secretion, activation and proliferation levels of IFN-γ and TNF-α. NUCC-0227579 downregulates NAD + synthesis in tumor cells, and inhibits the proliferation, migration and adhesion abilities of tumor cells under glutamine-deficient conditions. NUCC-0227579 significantly suppresses tumor growth in a humanized NSG mouse model of triple-negative breast cancer .
Cat. No.: HY-189215
CAS No.: 3087067-85-1
Target:
Influenza Virus RIG-I-like receptor (RLR) Toll-like Receptor (TLR) NF-κB Interleukin Related IFNAR Apoptosis Reactive Oxygen Species (ROS)
Research Areas:
Anti-Influenza agent 12 is an orally active inhibitor of influenza A virus infection. Anti-Influenza agent 12 inhibits RIG-I-mediated innate immune signaling and TLR3-mediated signaling pathways. Anti-Influenza agent 12 inhibits NF-κB phosphorylation and downregulates the expression levels of IRF3, ASC, iNOS, IL-4, IL-6, and IFN-α inflammatory genes. Anti-Influenza agent 12 inhibits viral nucleoprotein (NP) and matrix protein 2 (M2) mRNA transcription and protein synthesis. Anti-Influenza agent 12 inhibits virus-induced apoptosis, reduces ROS and NO production, and maintains mitochondrial membrane potential. Anti-Influenza agent 12 exhibits broad-spectrum activity against H1N1 and H3N2 subtypes, reduces viral load, and alleviates lung tissue damage. Anti-Influenza agent 12 can be used for research on influenza A virus infection .
Cat. No.: HY-L161
1,438 compounds
Cytokines are a kind of low molecular soluble proteins synthesized and secreted by immunogen, mitogen or other factors. They have functions of regulating innate and adaptive immune responses, promoting hematopoiesis, stimulating cell activation, proliferation and differentiation. The process of releasing a large number of cytokines is also called “Cytokine storm”, which can cause damage to many tissues and organs in the body. Cytokine is involved in the pathogenesis of many human diseases, including cancer, diabetes, chronic inflammatory diseases and so on. Cytokine inhibitors are a class of essential compounds that act by directly inhibiting the synthesis and release of cytokine or blocking the binding of cytokine to their receptors. Cytokine inhibitors are important compounds for the study of tumor and autoimmune diseases.
MCE designs a unique collection of 1,438 cytokine inhibitors, mainly targeting the receptor interleukin (IL), colony-stimulating factor (CSF), interferon (IFN), tumor necrosis factor (TNF), growth factor (GF) and chemokine, which is an effective tool for development and research of anti-cancer, anti-chronic inflammatory diseases and anti-autoimmune diseases compounds.
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
